ChemoCentryx, Inc. (NASDAQ:CCXI) Expected to Post Earnings of -$0.54 Per Share


Share on StockTwits

Wall Street brokerages expect ChemoCentryx, Inc. (NASDAQ:CCXI) to announce earnings per share (EPS) of ($0.54) for the current quarter, Zacks reports. Six analysts have issued estimates for ChemoCentryx’s earnings, with the lowest EPS estimate coming in at ($0.63) and the highest estimate coming in at ($0.51). ChemoCentryx reported earnings of $0.29 per share during the same quarter last year, which indicates a negative year over year growth rate of 286.2%. The firm is scheduled to report its next earnings report on Monday, August 9th.

According to Zacks, analysts expect that ChemoCentryx will report full year earnings of ($1.77) per share for the current year, with EPS estimates ranging from ($2.36) to ($1.31). For the next financial year, analysts forecast that the company will report earnings of ($0.97) per share, with EPS estimates ranging from ($1.52) to ($0.09). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow ChemoCentryx.

ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings data on Thursday, April 29th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.03). ChemoCentryx had a negative net margin of 58.10% and a negative return on equity of 17.23%.

CCXI has been the subject of several analyst reports. Stifel Nicolaus assumed coverage on shares of ChemoCentryx in a report on Monday, March 8th. They set a “buy” rating and a $93.00 price target for the company. TheStreet downgraded ChemoCentryx from a “c-” rating to a “d” rating in a research note on Tuesday, March 2nd. Raymond James increased their price objective on ChemoCentryx from $119.00 to $120.00 and gave the stock a “strong-buy” rating in a research report on Monday, March 8th. Finally, HC Wainwright boosted their target price on shares of ChemoCentryx from $83.00 to $101.00 and gave the stock a “buy” rating in a research report on Tuesday, March 2nd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. ChemoCentryx has an average rating of “Buy” and a consensus target price of $80.78.

In other news, insider Pui San Kwan sold 3,347 shares of the stock in a transaction dated Thursday, February 4th. The shares were sold at an average price of $65.00, for a total transaction of $217,555.00. Following the transaction, the insider now directly owns 4,621 shares in the company, valued at approximately $300,365. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Thomas A. Edwards sold 400 shares of the firm’s stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $70.04, for a total transaction of $28,016.00. Following the completion of the sale, the director now directly owns 120,957 shares in the company, valued at $8,471,828.28. The disclosure for this sale can be found here. Insiders sold a total of 53,626 shares of company stock valued at $3,632,810 over the last quarter. 9.30% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the business. Harbor Investment Advisory LLC raised its stake in shares of ChemoCentryx by 28.2% in the 1st quarter. Harbor Investment Advisory LLC now owns 1,091 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 240 shares in the last quarter. Profund Advisors LLC grew its holdings in shares of ChemoCentryx by 5.7% during the fourth quarter. Profund Advisors LLC now owns 4,499 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 241 shares during the last quarter. Genesee Capital Advisors LLC grew its stake in ChemoCentryx by 1.1% during the 4th quarter. Genesee Capital Advisors LLC now owns 28,176 shares of the biopharmaceutical company’s stock worth $1,744,000 after buying an additional 305 shares during the last quarter. Nisa Investment Advisors LLC grew its position in shares of ChemoCentryx by 19.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,130 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 350 shares during the last quarter. Finally, Valeo Financial Advisors LLC bought a new stake in ChemoCentryx in the 4th quarter valued at about $37,000. Hedge funds and other institutional investors own 80.67% of the company’s stock.

CCXI traded down $22.19 during trading on Tuesday, hitting $26.63. The stock had a trading volume of 25,293,343 shares, compared to its average volume of 787,298. The firm has a market capitalization of $1.86 billion, a P/E ratio of -39.75 and a beta of 1.70. The company has a debt-to-equity ratio of 0.05, a quick ratio of 10.12 and a current ratio of 10.12. ChemoCentryx has a twelve month low of $17.20 and a twelve month high of $70.29. The company’s 50-day moving average price is $49.82 and its 200 day moving average price is $57.11.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.

Featured Article: What is a SEC Filing?

Get a free copy of the Zacks research report on ChemoCentryx (CCXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.